Tag: M.W=150-200

The nomenclature of pyrimidines is straightforward. However, like other heterocyclics, tautomeric hydroxyl groups yield complications since they exist primarily in the cyclic amide form. 4595-59-9, formula is C4H3BrN2, Name is 5-Bromopyrimidine. For example, 2-hydroxypyrimidine is more properly named 2-pyrimidone. A partial list of trivial names of various pyrimidines exists. Safety of 5-Bromopyrimidine.

Khan, Ilham;Khalid, Muhammad;Adeel, Muhammad;Niaz, Shah Irum;Shafiq, Iqra;Muhammad, Shabbir;Braga, Ataualpa Albert Carmo research published 《 Palladium-catalyzed synthesis of 5-(arylated) pyrimidines, their characterization, electronic communication, and non-linear optical evaluations》, the research content is summarized as follows. In this study, new derivatives of pyrimidines I [R¹ = 4-methylsulfanyl, 4-Ph, 4-trifluoromethoxy, 2,3-dichloro] were synthesized through Suzuki-Miyaura coupling and assessed by ¹H NMR, ¹³C NMR, FT-IR and UV/Visible anal. Furthermore, computational study such as spectroscopic, frontier MO (FMO), natural bond orbital (NBO) and the mol. electrostatic potential (MEP) was performed at M06/6-311G** to obtain comprehensive insights into electronic communications and the structural property relationship for synthesized compounds I. The maximum exptl. absorption (λ_Exp) for compounds I [R¹ = 4-Ph, 4-methylsulfanyl, 4-trifluoromethoxy, 2,3-dichloro] was obtained at 260, 301, 248, and 233 nm, resp. in methanol, which displayed good agreement with theor. (λ_DFT) result 279, 298, 247, and 233 nm, resp. Moreover, different functional(s) such as HF, M06, M062X, CAM-B3LYP, and LC-BLYP with basis sets 6-311G** were utilized to compute the average polarizability α, total dipole moment (μ_tot) and hyperpolarizability (β_tot) values. Among the tested methods, highest μ_tot value (3.5465 D) was observed for compoundI [R¹ = 2,3-dichloro] and the lowest value (0.2680 D) for compound I [R¹ = 4-trifluoromethoxy] through HF method. Consequently, the LC-BLYP method also showed the highest μ_tot value (3.4689 D) for compound I [R¹ = 2,3-dichloro] and the lowest value (0.3123 D) of compound I [R¹ = 4-trifluoromethoxy]. Moreover, other methods: CAM-B3LYP, M062X, and M06 showed almost similar values for all compounds I with similar trends. The M06 method showed the largest α values (190.779, 149.331, 130.430 and 138.964 a.u.) for compounds I [R¹ = 4-Ph, 4-methylsulfanyl, 4-trifluoromethoxy, 2,3-dichloro] resp. In contrast, the HF method showed the least α values (178.166, 140.356, 121.848, and 128.994 a.u.) for compounds I [R¹ = 4-Ph, 4-methylsulfanyl, 4-trifluoromethoxy, 2,3-dichloro] resp. The other methods (CAMB3LYP, M062X, and LC-BLYP) indicated nearly parallel (α) values. Moreover, the (β_tot) values (604.898, 344.234, 41.628, and 299.958 a.u.) obtained with M06 method for compounds I [R¹ = 4-Ph, 4-methylsulfanyl, 4-trifluoromethoxy, 2,3-dichloro] resp., were higher compared with urea (β_tot = 69.399 a.u.).

Safety of 5-Bromopyrimidine, 5-Bromopyrimidine is a reactive intermediate that is used in the synthesis of 4-methoxyphenylboronic acid. 5-Bromopyrimidine has been shown to be nucleophilic, reacting with β-amino acids under basic conditions to form the corresponding 2-bromo amide. It also undergoes cross-coupling reactions with halides and can be used as a building block for other organic compounds. 5-Bromopyrimidine has optical properties that are characteristic of aromatic molecules, including strong absorption bands in the ultraviolet region and visible light region.
5-Bromopyrimidine undergoes direct metallation with lithuium diisopropylamide to yield 4-lithio-5-bromopyrimidine., 4595-59-9.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives, including the nucleotides cytosine, thymine and uracil, thiamine (vitamin B1) and alloxan. 4595-59-9, formula is C4H3BrN2, Name is 5-Bromopyrimidine. It is also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Related Products of 4595-59-9.

Khan, Ilham;Khalid, Muhammad;Adeel, Muhammad;Khan, Muhammad Usman;Khan, Muhammad Sohail;Ahmad, Naseeb;Ali, Akbar;Akram, Muhammad research published 《 Palladium-catalyzed synthesis of pyrimidine substituted diaryl ethers through Suzuki Miyaura coupling reactions: Experimental and DFT studies》, the research content is summarized as follows. Aryl and hetero-aryl substituted pyrimidine derivatives demonstrate widespread applications in nonlinear optics (NLO), agrochem. and therapeutic drugs. Therefore, 2-(4-phenoxyphenyl)pyrimidine (2-PPP) and 5-(4-phenoxyphenyl) pyrimidine (5-PPP) were synthesized by palladium-catalyzed Suzuki coupling approach. The structure elucidation of synthesized products was done by ¹H-NMR, ¹³C-NMR, and UV-vis spectroscopic analyses. The natural bond orbital (NBO) anal. was performed using d. functional theory (DFT) assisted M06/6-311G** functional, which confirmed the existence of delocalization process and the hyper-conjugative interaction with representative transitions as π(C10-N16)→π*(C14-N17) and π(C26-N30)→π*(C9-N31) having stabilization energies of 36.30 and 36.55 kcal/mol for 2-PPP and 5-PPP, resp. The small energy ΔE LUMO HOMO gap as 5.330 eV in 2-PPP and 4.975 eV in 5-PPP was evident from the frontier MO (FMO) anal., computed at TD-DFT/M06/6-311G** level, Both the NBO and the FMO anal. predicted promising NLO mol. response. Furthermore, HF, LC-BLYP, CAM-B3LYP, M06-2X, and M06 methods, along with the 6-311G** basis set, were utilized to acquire the NLO findings of 2-PPP and 5-PPP. M06 and HF methods indicated the largest and lowest values of average polarizability α and first hyperpolarizability (β_tot), resp. for both the compounds 2-PPP and 5-PPP. The α and β_tot values of 2-PPP and 5-PPP were observed as 7.0 and 7.3 times and 15 and 36 times higher than the urea mol., resp. Both compounds hold fine NLO characteristics, thus recommended for future NLO applications.

Related Products of 4595-59-9, 5-Bromopyrimidine is a reactive intermediate that is used in the synthesis of 4-methoxyphenylboronic acid. 5-Bromopyrimidine has been shown to be nucleophilic, reacting with β-amino acids under basic conditions to form the corresponding 2-bromo amide. It also undergoes cross-coupling reactions with halides and can be used as a building block for other organic compounds. 5-Bromopyrimidine has optical properties that are characteristic of aromatic molecules, including strong absorption bands in the ultraviolet region and visible light region.
5-Bromopyrimidine undergoes direct metallation with lithuium diisopropylamide to yield 4-lithio-5-bromopyrimidine., 4595-59-9.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Pyrimidine is a nitrogenous base similar to benzene (a six-membered ring) and includes cytosine, thymine, and uracil as bases used for DNA or RNA. 4595-59-9, formula is C4H3BrN2, Name is 5-Bromopyrimidine. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Quality Control of 4595-59-9.

Khandaka, Himanshu;Sharma, Kamal Nayan;Joshi, Raj Kumar research published 《 Aerobic Cu and amine free Sonogashira and Stille couplings of aryl bromides/chlorides with a magnetically recoverable Fe₃O₄@SiO₂ immobilized Pd(II)-thioether containing NHC》, the research content is summarized as follows. Two value added C-C cross coupling reactions; Sonogashira and Stille couplings were achieved at milder conditions in the catalytic presence of a magnetically recoverable heterogeneous catalyst Fe₃O₄@SiO₂ immobilized Pd(II)-thioether containing NHC. The catalyst was earlier reported for Suzuki-Miyaura reaction and as an extension of its catalytic efficiency, the Stille and Sonogashira cross coupling reactions under aerobic condition had been explored in present report. The Sonogashira coupling of aryl bromides and terminal alkynes produced an excellent yield (∼96% at 0.25 mol% Pd) of the desired coupling product under copper and amines free conditions. Moreover, an excellent Stille coupling of readily available and more latent aryl chlorides and trialkylstannane was obtained (yields up to 95% at 0.25 mol% Pd) in absence of toxic fluorides additives. The broad substrate scope of the catalyst for both the coupling reactions and the magnetically recoverable feature of catalyst made this reaction highly desirable for industrial applications of present heterogeneous catalysis.

Quality Control of 4595-59-9, 5-Bromopyrimidine is a reactive intermediate that is used in the synthesis of 4-methoxyphenylboronic acid. 5-Bromopyrimidine has been shown to be nucleophilic, reacting with β-amino acids under basic conditions to form the corresponding 2-bromo amide. It also undergoes cross-coupling reactions with halides and can be used as a building block for other organic compounds. 5-Bromopyrimidine has optical properties that are characteristic of aromatic molecules, including strong absorption bands in the ultraviolet region and visible light region.
5-Bromopyrimidine undergoes direct metallation with lithuium diisopropylamide to yield 4-lithio-5-bromopyrimidine., 4595-59-9.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Pyrimidine is a nitrogenous base similar to benzene (a six-membered ring) and includes cytosine, thymine, and uracil as bases used for DNA or RNA. 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Product Details of C4HCl2FN2.

Kim, Eunha;Yang, Katherine S.;Kohler, Rainer H.;Dubach, John M.;Mikula, Hannes;Weissleder, Ralph research published 《 Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression》, the research content is summarized as follows. Bruton’s tyrosine kinase (Btk) is intricately involved in anti-apoptotic signaling pathways in cancer and in regulating innate immune response. A number of Btk inhibitors are in development for use in treating B-cell malignancies and certain immunol. diseases. To develop robust companion imaging diagnostics for in vivo use, we set out to explore the effects of red wavelength fluorochrome modifications of two highly potent irreversible Btk inhibitors, Ibrutinib and AVL-292. Surprisingly, we found that subtle chem. differences in the fluorochrome had considerable effects on target localization. Based on iterative designs, we developed a single optimized version with superb in vivo imaging characteristics enabling single cell Btk imaging in vivo. This agent (Ibrutinib-SiR-COOH) is expected to be a valuable chem. tool in deciphering Btk biol. in cancer and host cells in vivo.

Product Details of C4HCl2FN2, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., 2927-71-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The systematic study of pyrimidines began in 1884 with Pinner, who synthesized derivatives by condensing ethyl acetoacetate with amidines. Pinner first proposed the name “pyrimidin” in 1885. 65-86-1, formula is C5H4N2O4, Name is 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid. The parent compound was first prepared by Gabriel and Colman in 1900, by conversion of barbituric acid to 2,4,6-trichloropyrimidine followed by reduction using zinc dust in hot water. Safety of 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid.

Kim, Hye-Shin;Arellano, Karina;Park, Haryung;Todorov, Svetoslav D.;Kim, Bobae;Kang, Hyeji;Park, Yu Jin;Suh, Dong Ho;Jung, Eun Sung;Ji, Yosep;Holzapfel, Wilhelm H. research published 《 Assessment of the safety and anti-inflammatory effects of three Bacillus strains in the respiratory tract》, the research content is summarized as follows. Chronic respiratory diseases are part of accumulating health problems partly due to worldwide increase in air pollution. By their antimicrobial and immunomodulatory properties, some probiotics constitute promising alternatives for the prevention and treatment of chronic respiratory diseases. We have isolated Bacillus strains from Korean fermented foods and selected three potentially probiotic strains (two Bacillus subtilis and one Bacillus amyloliquefaciens) based on safety, antimicrobial efficacy, activity against airborne pathogens and their immunomodulatory properties in vivo. Safety evaluation included in silico anal. for confirming absence of virulence genes. Safety for the respiratory tract was confirmed by an in vivo pathogenicity test using a murine model. Antimicrobial activity was displayed against several airborne pathogens. Potential antimicrobial metabolites such as 2,3-butanediol and propylene glycol were identified as possible antagonistic agents. Immunomodulatory properties in vitro were confirmed by upregulation of IL-10 expression in a macrophage cell line. Intranasal instillation and inhalation in an ovalbumin (OVA)-induced lung inflammation murine model reduced T helper type 2 (Th2) cytokines at transcriptional and protein levels in the lungs. The safety and potentially beneficial role of these Bacillus strains could be demonstrated for the respiratory tract of a murine model. The obtained 16S rRNA partial sequences were deposited in the gene bank as accession numbers MW709435 (B. subtilis 3), MW709437(B. subtilis 281), and MW709530 (B. amyloliquefaciens 298).

65-86-1, Orotic acid anhydrous is a hydrogen bonding interaction that can be found in biological systems. It plays a role in the physiological effects of orotic acid, which is a metabolite of uridine and an intermediate in the synthesis of pyrimidine nucleotides. Orotic acid has antimicrobial properties and has been shown to inhibit enzyme activities involved in energy metabolism, such as polymerase chain reaction (PCR) and adenosine triphosphate (ATP) synthase. Orotic acid also inhibits the growth of bacteria, fungi, and parasites. Orotic acid anhydrous is used for treating myocardial infarcts or brain functions. The untreated group was given no treatment at all.
Orotic acid, also known as orotate or orotsaeure, belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring. Orotic acid exists as a solid, slightly soluble (in water), and a moderately acidic compound (based on its pKa). Orotic acid has been found in human liver and pancreas tissues, and has also been primarily detected in saliva, feces, urine, and blood. Within the cell, orotic acid is primarily located in the cytoplasm and mitochondria. Orotic acid exists in all eukaryotes, ranging from yeast to humans. Orotic acid participates in a number of enzymatic reactions. In particular, Orotic acid can be biosynthesized from L-dihydroorotic acid and quinone; which is mediated by the enzyme dihydroorotate dehydrogenase (quinone), mitochondrial. In addition, Orotic acid and phosphoribosyl pyrophosphate can be converted into orotidylic acid through its interaction with the enzyme uridine monophosphate synthetase isoform a. In humans, orotic acid is involved in the pyrimidine metabolism pathway. Orotic acid is also involved in several metabolic disorders, some of which include the mngie (mitochondrial neurogastrointestinal encephalopathy) pathway, dihydropyrimidinase deficiency, UMP synthase deficiency (orotic aciduria), and Beta ureidopropionase deficiency. Outside of the human body, orotic acid can be found in a number of food items such as green vegetables, alaska blueberry, chickpea, and colorado pinyon. This makes orotic acid a potential biomarker for the consumption of these food products. Orotic acid is a potentially toxic compound. Orotic acid has been found to be associated with several diseases known as phosphoenolpyruvate carboxykinase deficiency 1, cytosolic and hyperornithinemia-hyperammonemia-homocitrullinuria; orotic acid has also been linked to several inborn metabolic disorders including n-acetylglutamate synthetase deficiency, lysinuric protein intolerance, and ornithine transcarbamylase deficiency.
Orotic acid appears as white crystals or crystalline powder.
Orotic acid is a pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. It has a role as a metabolite, an Escherichia coli metabolite and a mouse metabolite. It derives from a uracil. It is a conjugate acid of an orotate., Safety of 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives, including the nucleotides cytosine, thymine and uracil, thiamine (vitamin B1) and alloxan. 65-86-1, formula is C5H4N2O4, Name is 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid. It is also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Quality Control of 65-86-1.

Kim, Hyung Joon;Kim, Ju Hyun;Yeon, Jong Eun;Seo, Yeon Seok;Jang, Jeong Won;Cho, Yong Kyun;Jang, Byoung Kuk;Han, Byung Hoon;Lee, Changhyeong;Lee, Joon Hyeok;Yoon, Jung-Hwan;Kim, Kang Mo;Kim, Moon Young;Kim, Do Young;Park, Neung Hwa;Cho, Eun Young;Lee, June Sung;Lee, Jin-Woo;Kim, In Hee;Song, Byung-Cheol;Lee, Byung-Seok;Kwon, Oh Sang research published 《 A multi-center, double-blind randomized controlled phase III clinical trial to evaluate the antiviral activity and safety of DA-2802 (tenofovir disoproxil orotate) and viread (tenofovir disoproxil fumarate) in chronic hepatitis b patients》, the research content is summarized as follows. Background: Tenofovir disoproxil fumarate (TDF, Viread) had been used as a standard treatment option of chronic hepatitis B (CHB). This clin. trial was conducted to evaluate the efficacy and safety of DA-2802 (tenofovir disoproxil orotate) compared to TDF. Methods: The present study was a double blind randomized controlled trial. Patients with CHB were recruited from 25 hospitals in Korea and given DA-2802 at a dose of 319 mg once daily or Viread at a dose of 300 mg once daily for 48 wk from March 2017 to Jan. 2019. Change in hepatitis B virus (HBV) DNA level at week 48 after dosing compared to baseline was the primary efficacy endpoint. Secondary efficacy endpoints were proportions of subjects with undetectable HBV DNA, those with normal alanine aminotransferase (ALT) levels, and those with loss of hepatitis B envelop antigen (HBeAg), those with loss of hepatitis B surface antigen (HBsAg). Adverse events (AEs) were also investigated. Results: A total of 122 patients (DA-2802 group: n = 61, Viread group: n = 61) were used as full anal. set for efficacy anal. Mean age, proportion of males, laboratory results and virol. characteristics were not different between the two groups. The change in HBV DNA level at week 48 from baseline was -5.13 ± 1.40 in the DA-2802 group and -4.97 ± 1.40 log10 copies/mL in the Viread group. The anal. of primary endpoint using the nonparametric anal. of covariance showed statistically significant results (P < 0.001), which confirmed non-inferiority of DA-2802 to Viread by a prespecified noninferiority margin of 1. The proportion of undetectable HBV DNA was 78.7% in the DA-2802 group and 75.4% in the Viread group (P = 0.698). The proportion of subjects who had normal ALT levels was 75.4% in the DA-2802 group and 73.3% in the Viread group (P = 0.795). The proportion of those with HBeAg loss was 8.1% in the DA-2802 group and 10.8% in the Viread group (P = 1.000). No subject showed HBsAg loss. The frequency of AEs during treatment was similar between the two groups. Most AEs were mild to moderate in severity. Conclusion: DA-2802 is considered an effective and safe treatment for patients with CHB.

Quality Control of 65-86-1, Orotic acid anhydrous is a hydrogen bonding interaction that can be found in biological systems. It plays a role in the physiological effects of orotic acid, which is a metabolite of uridine and an intermediate in the synthesis of pyrimidine nucleotides. Orotic acid has antimicrobial properties and has been shown to inhibit enzyme activities involved in energy metabolism, such as polymerase chain reaction (PCR) and adenosine triphosphate (ATP) synthase. Orotic acid also inhibits the growth of bacteria, fungi, and parasites. Orotic acid anhydrous is used for treating myocardial infarcts or brain functions. The untreated group was given no treatment at all.
Orotic acid, also known as orotate or orotsaeure, belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring. Orotic acid exists as a solid, slightly soluble (in water), and a moderately acidic compound (based on its pKa). Orotic acid has been found in human liver and pancreas tissues, and has also been primarily detected in saliva, feces, urine, and blood. Within the cell, orotic acid is primarily located in the cytoplasm and mitochondria. Orotic acid exists in all eukaryotes, ranging from yeast to humans. Orotic acid participates in a number of enzymatic reactions. In particular, Orotic acid can be biosynthesized from L-dihydroorotic acid and quinone; which is mediated by the enzyme dihydroorotate dehydrogenase (quinone), mitochondrial. In addition, Orotic acid and phosphoribosyl pyrophosphate can be converted into orotidylic acid through its interaction with the enzyme uridine monophosphate synthetase isoform a. In humans, orotic acid is involved in the pyrimidine metabolism pathway. Orotic acid is also involved in several metabolic disorders, some of which include the mngie (mitochondrial neurogastrointestinal encephalopathy) pathway, dihydropyrimidinase deficiency, UMP synthase deficiency (orotic aciduria), and Beta ureidopropionase deficiency. Outside of the human body, orotic acid can be found in a number of food items such as green vegetables, alaska blueberry, chickpea, and colorado pinyon. This makes orotic acid a potential biomarker for the consumption of these food products. Orotic acid is a potentially toxic compound. Orotic acid has been found to be associated with several diseases known as phosphoenolpyruvate carboxykinase deficiency 1, cytosolic and hyperornithinemia-hyperammonemia-homocitrullinuria; orotic acid has also been linked to several inborn metabolic disorders including n-acetylglutamate synthetase deficiency, lysinuric protein intolerance, and ornithine transcarbamylase deficiency.
Orotic acid appears as white crystals or crystalline powder.
Orotic acid is a pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. It has a role as a metabolite, an Escherichia coli metabolite and a mouse metabolite. It derives from a uracil. It is a conjugate acid of an orotate., 65-86-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The systematic study of pyrimidines began in 1884 with Pinner, who synthesized derivatives by condensing ethyl acetoacetate with amidines. Pinner first proposed the name “pyrimidin” in 1885. 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. The parent compound was first prepared by Gabriel and Colman in 1900, by conversion of barbituric acid to 2,4,6-trichloropyrimidine followed by reduction using zinc dust in hot water. Reference of 2927-71-1.

Kim, Juhyeon;Moon, Byung Seok;Lee, Byung Chul;Lee, Ho-Young;Kim, Hak-Joong;Choo, Hyunah;Pae, Ae Nim;Cho, Yong Seo;Min, Sun-Joon research published 《 A Potential PET Radiotracer for the 5-HT_2C Receptor: Synthesis and in Vivo Evaluation of 4-(3-[¹⁸F]fluorophenethoxy)pyrimidine》, the research content is summarized as follows. The serotonin 2C receptor subtype (5-HT2C) is an excitatory 5-HT receptor widely distributed throughout the central nerve system. As the 5-HT2C receptor displays multiple actions on various neurotransmitter systems including glutamate, dopamine, epinephrine and γ-aminobutyric acid (GABA), abnormalities of the 5-HT2C receptor are associated with psychiatric diseases such as depression, schizophrenia, drug abuse, and anxiety. Up to date, three kinds of 5-HT2C PET radiotracers such as [11C]N-methylated arylazepine (1), [11C]WAY-163909 (2), [18F]fluorophenylcyclopropane (3) have been developed, but they may not be suitable for in vivo 5-HT2C imaging study due to their modest specific binding. Herein, the synthesis and in vivo evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine [18F]4 as a potential PET radiotracer for the 5-HT2C receptor is described. [18F]4 was synthesized by nucleophilic aromatic substitution of diaryliodonium precursor 17a with a 7.8 ± 2.7% (n = 6, decay corrected) radiochem. yield and over 99% radiochem. purity, showing an 89 ± 14 GBq/μmol specific radioactivity. The in vivo PET imaging studies of [18F]4 with or without locaserin, an FDA approved selective 5-HT2C agonist, demonstrated that [18F]4 exhibits a high level of specific binding to 5-HT2C receptors in the rat brain.

Reference of 2927-71-1, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., 2927-71-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The nomenclature of pyrimidines is straightforward. However, like other heterocyclics, tautomeric hydroxyl groups yield complications since they exist primarily in the cyclic amide form. 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. For example, 2-hydroxypyrimidine is more properly named 2-pyrimidone. A partial list of trivial names of various pyrimidines exists. Formula: C4HCl2FN2.

Kim, Juhyeon;Jo, Hanbyeol;Lee, Hyunseung;Choo, Hyunah;Kim, Hak Joong;Pae, Ae Nim;Cho, Yong Seo;Min, Sun-Joon research published 《 Identification of optically active pyrimidine derivatives as selective 5-HT_2C modulators》, the research content is summarized as follows. A series of pyrimidine derivatives I [R = 2-F, 3-F, 4-F; R¹ = H, Me; n = 0, 2] was synthesized and evaluated for their binding affinities toward 5-HT_2C receptors. With regard to designed mols. I, the influence of size of alkyl ether and the absolute configuration of a stereogenic center on the 5-HT_2C binding affinity and selectivity was studied. The most promising diastereomeric mixtures I [R = 3-F, 4-F; R¹ = Me; n = 0] were selected in the initial radioligand binding assay and they were further synthesized as optically active forms starting from optically active alcs. RC₆H₄CH₂CH(Me)OH [stereo – R or S] by enzymic kinetic resolution Pyrimidine analog I [R = 4-F, R¹ = Me, n = 0, stereo – (R,R)] displayed an excellent 5-HT_2C binding affinity with good selectivity values against a broad range of other 5-HT receptor subtypes.

Formula: C4HCl2FN2, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., 2927-71-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The systematic study of pyrimidines began in 1884 with Pinner, who synthesized derivatives by condensing ethyl acetoacetate with amidines. Pinner first proposed the name “pyrimidin” in 1885. 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. The parent compound was first prepared by Gabriel and Colman in 1900, by conversion of barbituric acid to 2,4,6-trichloropyrimidine followed by reduction using zinc dust in hot water. Safety of 2,4-Dichloro-5-fluoropyrimidine.

Kim, Juhyeon;Kim, Yoon Jung;Londhe, Ashwini M.;Pae, Ae Nim;Choo, Hyunah;Kim, Hak Joong;Min, Sun-Joon research published 《 Synthesis and biological evaluation of disubstituted pyrimidines as selective 5-HT2C agonists》, the research content is summarized as follows. The synthesis of disubstituted pyrimidine derivatives I [R¹ = 3-F, 4-F; n = 0, 1, 2; R² = piperazin-1-yl, (2R)-2-methylpiperazin-1-yl, 1,4-diazepan-1-yl], II [R³ = (2R)-2-(3-fluorophenyl)propyl, (2R)-2-(4-fluorophenyl)propyl, 3-fluorophenyl, 4-fluorophenyl; R⁴ = 1,4-diazepan-1-yl, [(3R)-pyrrolidin-3-yl]aminyl, 2,7-diazaspiro[4.4]nonan-2-yl, etc.] and their biol. evaluation as selective 5-HT2C agonists were described. To improve selectivity for 5-HT2C over other subtypes, two series of disubstituted pyrimidines with fluorophenylalkoxy groups at either the 5-position or 4-position and varying cyclic amines at the 2-position were synthesized. The in vitro cell-based assay and binding assay identified compounds II [R³ = (2R)-2-(3-fluorophenyl)propyl, R⁴ = 1,4-diazepan-1-yl (I); R³ = (2R)-2-(4-fluorophenyl)propyl, R⁴ = 1,4-diazepan-1-yl] as potent 5-HT2C agonists. Further studies on selectivity to 5-HT subtypes and drug-like properties indicated that 2,4-disubstituted pyrimidine (I) showed a highly agonistic effect on the 5-HT2C receptor, with excellent selectivity, as well as exceptional drug-like properties, including high plasma and microsomal stability, along with low CYP inhibition. Thus, pyrimidine (I) could be considered a viable lead compound as a 5-HT2C selective agonist.

Safety of 2,4-Dichloro-5-fluoropyrimidine, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., 2927-71-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The systematic study of pyrimidines began in 1884 with Pinner, who synthesized derivatives by condensing ethyl acetoacetate with amidines. Pinner first proposed the name “pyrimidin” in 1885. 4595-59-9, formula is C4H3BrN2, Name is 5-Bromopyrimidine. The parent compound was first prepared by Gabriel and Colman in 1900, by conversion of barbituric acid to 2,4,6-trichloropyrimidine followed by reduction using zinc dust in hot water. Quality Control of 4595-59-9.

Kim, Weonjeong;Koo, Jangwoo;Lee, Hong Geun research published 《 Benzylic C(sp³)-C(sp²) cross-coupling of indoles enabled by oxidative radical generation and nickel catalysis》, the research content is summarized as follows. A mechanistically unique functionalization strategy for a benzylic C(sp³)-H bond was developed based on facile oxidation event of indole substrates. This novel pathway was initiated by efficient radical generation at benzylic position of substrate, with subsequent transition metal catalysis to complete overall transformation. Ultimately, an aryl or an acyl group could be effectively delivered from an aryl (pseudo)halide or an acid anhydride coupling partner, resp. The developed method utilized mild conditions and exhibited a wide substrate scope for both substituted indoles and C(sp²)-based reaction counterparts. Mechanistic studies showed that competitive hydrogen atom transfer (HAT) processes, which were frequently encountered in conventional methods, are not involved in the product formation process of the developed strategy.

4595-59-9, 5-Bromopyrimidine is a reactive intermediate that is used in the synthesis of 4-methoxyphenylboronic acid. 5-Bromopyrimidine has been shown to be nucleophilic, reacting with β-amino acids under basic conditions to form the corresponding 2-bromo amide. It also undergoes cross-coupling reactions with halides and can be used as a building block for other organic compounds. 5-Bromopyrimidine has optical properties that are characteristic of aromatic molecules, including strong absorption bands in the ultraviolet region and visible light region.
5-Bromopyrimidine undergoes direct metallation with lithuium diisopropylamide to yield 4-lithio-5-bromopyrimidine., Quality Control of 4595-59-9

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia